Table 3 Thyroid hormone levels of the PWS patients with C-HT in the different groups

Age Groups

1 m-0.99y (n = 18)

11.48 ± 1.37 (8.58–13.11)

Ref. (13.17–22.33)

2.48 ± 1.68 (0.02–7.38)

Ref. (0.36–7.63)

1y-2.99y (n = 12)

12.88 ± 1.77 (9.19–14.43)

Ref. (14.45–22.74)

2.55 ± 1.48 (0.41–4.86)

Ref. (0.38–7.31)

3y-5.99y (n = 12)

14.18 ± 0.75 (13.10–15.39)

Ref. (15.49–22.38)

2.78 ± 0.91 (1.28–4.22)

Ref. (0.65–7.18)

6y-8.99y (n = 4)

13.02 ± 0.75 (12.06–13.88)

Ref. (14.42–22.22)

2.05 ± 0.90 (0.96–3.09)

Ref. (0.79–6.06)

9y-11.99y (n = 1)

11.28

Ref. (11.5–22.7)

1.53

Ref. (0.51–4.94)

Nutritional Phases Groups

Phase 1a (n = 15)

11.59 ± 1.38 (8.58–13.11)

2.68 ± 1.70 (0.54–7.38)

Phase 1b (n = 12)

12.13 ± 1.89 (9.19–14.43)

2.43 ± 1.64 (0.02–4.86)

Phase 2a (n = 10)

14.26 ± 0.60 (13.56–15.39)

2.56 ± 0.84 (1.41–4.22)

Phase 2b (n = 7)

13.66 ± 0.79 (12.94–15.12)

2.54 ± 0.93 (1.28–4.13)

Phase 3 (n = 3)

12.41 ± 1.33 (11.28–13.88)

1.86 ± 1.10 (0.96–3.09)

Genotype

Deletion (n = 31)

12.31 ± 1.82 (8.58–15.12)

2.51 ± 1.50 (0.02–7.38)

UPD (n = 13)

13.50 ± 1.14 (11.28–15.39)

2.81 ± 1.04 (1.28–4.86)

Unclassified (n = 3)

12.61 ± 0.95 (11.84–13.67)

1.37 ± 0.34 (1.01–1.69)

rhGH therapy

Yes (n = 35)

12.66 ± 1.56 (8.58–14.88)

2.55 ± 1.50 (0.02–7.38)

during rhGH therapy (n = 9)

13.31 ± 1.14 (11.28–14.84)

2.05 ± 0.88 (0.54–3.30)

No (n = 12)

12.63 ± 2.07 (9.12–15.39)

2.42 ± 0.93 (0.77–4.22)

Total C-HT(n = 47)

12.66 ± 1.68 (8.58–15.39)

2.51 ± 1.37 (0.02–7.38)